{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T01:37:46Z","timestamp":1787881066257,"version":"build-2784847793"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T00:00:00Z","timestamp":1711584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The use of extracorporeal membrane oxygenation (ECMO) may alter blood levels of several drugs, including antibiotics, leading to under dosing of these drugs and thus to potential treatment failure. No data exist on pharmacokinetics of new antimicrobial, in particular ceftazidime\/avibactam. We therefore perform this study to evaluate ceftazidime\/avibactam blood levels in ECMO patients and find factors associated with underdosing.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Retrospective observational study of patients on ECMO having received ceftazidime\/avibactam and in whom trough blood levels of ceftazidime and avibactam were available. Main outcome measurement was the number of patients with ceftazidime and avibactam blood levels above predefined cut-off values, derived from the European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints for Enterobacteriaceae and Pseudomonas aeruginosa, namely 8\u2005mg\/L for ceftazidime and 4\u2005mg\/L for avibactam, and explored factors associated with underdosing.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Twenty-three ceftazidime\/avibactam trough levels were available in 14 ECMO patients, all of them having received veno-venous ECMO for SARS-CoV-2-associated pneumonia. Although ceftazidime levels were above 8\u2005mg\/L in all except one patient, nine (39%) of the avibactam dosages were below 4\u2005mg\/L. Increased renal clearance (creatinine clearance\u200a&amp;gt;\u200a130\u2005mL\/min) was the main factor associated with under dosing, since 7 out of the 10 dosages below the predefined cut-offs were measured in patients with this condition.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In ECMO patients receiving ceftazidime\/avibactam, ceftazidime and avibactam serum levels are above EUCAST breakpoints in most cases, justifying the use of normal dosing in ECMO patients. Increased renal clearance may lead to ceftazidime and avibactam under dosing.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkae091","type":"journal-article","created":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T17:08:23Z","timestamp":1711645703000},"page":"1182-1186","source":"Crossref","is-referenced-by-count":12,"title":["Ceftazidime\/avibactam serum concentration in patients on ECMO"],"prefix":"10.1093","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9154-0923","authenticated-orcid":false,"given":"Ana\u00efs","family":"Curtiaud","sequence":"first","affiliation":[{"name":"Service de m\u00e9decine Intensive R\u00e9animation, Sorbonne Universit\u00e9, Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, Institut de Cardiologie, Assistance Publique-H\u00f4pitaux de Paris , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Petit","sequence":"additional","affiliation":[{"name":"Service de m\u00e9decine Intensive R\u00e9animation, Sorbonne Universit\u00e9, Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, Institut de Cardiologie, Assistance Publique-H\u00f4pitaux de Paris , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Chommeloux","sequence":"additional","affiliation":[{"name":"Service de m\u00e9decine Intensive R\u00e9animation, Sorbonne Universit\u00e9, Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, Institut de Cardiologie, Assistance Publique-H\u00f4pitaux de Paris , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pineton de Chambrun","sequence":"additional","affiliation":[{"name":"Service de m\u00e9decine Intensive R\u00e9animation, Sorbonne Universit\u00e9, Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, Institut de Cardiologie, Assistance Publique-H\u00f4pitaux de Paris , Paris , France"},{"name":"Sorbonne Universit\u00e9, GRC 30, RESPIRE, UMRS 1166, ICAN Institute of Cardiometabolism and Nutrition , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Hekimian","sequence":"additional","affiliation":[{"name":"Service de m\u00e9decine Intensive R\u00e9animation, Sorbonne Universit\u00e9, Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, Institut de Cardiologie, Assistance Publique-H\u00f4pitaux de Paris , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Service de m\u00e9decine Intensive R\u00e9animation, Sorbonne Universit\u00e9, Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, Institut de Cardiologie, Assistance Publique-H\u00f4pitaux de Paris , Paris , France"},{"name":"Sorbonne Universit\u00e9, GRC 30, RESPIRE, UMRS 1166, ICAN Institute of Cardiometabolism and Nutrition , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Combes","sequence":"additional","affiliation":[{"name":"Service de m\u00e9decine Intensive R\u00e9animation, Sorbonne Universit\u00e9, Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, Institut de Cardiologie, Assistance Publique-H\u00f4pitaux de Paris , Paris , France"},{"name":"Sorbonne Universit\u00e9, GRC 30, RESPIRE, UMRS 1166, ICAN Institute of Cardiometabolism and Nutrition , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7424-2705","authenticated-orcid":false,"given":"Charles-Edouard","family":"Luyt","sequence":"additional","affiliation":[{"name":"Service de m\u00e9decine Intensive R\u00e9animation, Sorbonne Universit\u00e9, Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, Institut de Cardiologie, Assistance Publique-H\u00f4pitaux de Paris , Paris , France"},{"name":"Sorbonne Universit\u00e9, GRC 30, RESPIRE, UMRS 1166, ICAN Institute of Cardiometabolism and Nutrition , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,3,28]]},"reference":[{"key":"2024050202521434800_dkae091-B1","doi-asserted-by":"crossref","first-page":"6898","DOI":"10.3390\/jcm11236898","article-title":"Pharmacokinetics, pharmacodynamics, and dosing considerations of novel \u03b2-lactams and \u03b2-lactam\/\u03b2-lactamase inhibitors in critically ill adult patients: focus on obesity, augmented renal clearance, renal replacement therapies, and extracorporeal membrane oxygenation","volume":"11","author":"Bakdach","year":"2022","journal-title":"JCM"},{"key":"2024050202521434800_dkae091-B2","doi-asserted-by":"crossref","first-page":"6907","DOI":"10.2147\/IDR.S390635","article-title":"Mortality-related risk factors and novel antimicrobial regimens for carbapenem-resistant enterobacteriaceae infections: a systematic review","volume":"15","author":"Hu","year":"2022","journal-title":"Infect Drug Resist"},{"key":"2024050202521434800_dkae091-B3","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s13613-020-00775-4","article-title":"Ventilator-associated pneumonia in patients with SARS-CoV-2-associated acute respiratory distress syndrome requiring ECMO: a retrospective cohort study","volume":"10","author":"Luyt","year":"2020","journal-title":"Ann Intensive Care"},{"key":"2024050202521434800_dkae091-B4","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1164\/rccm.202207-1393OC","article-title":"Antimicrobial exposures in critically ill patients receiving extracorporeal membrane oxygenation","volume":"207","author":"Shekar","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2024050202521434800_dkae091-B5","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1186\/s13054-020-03397-1","article-title":"Antibiotic therapeutic drug monitoring in intensive care patients treated with different modalities of extracorporeal membrane oxygenation (ECMO) and renal replacement therapy: a prospective, observational single-center study","volume":"24","author":"K\u00fchn","year":"2020","journal-title":"Crit Care"},{"key":"2024050202521434800_dkae091-B6","year":"2024"},{"key":"2024050202521434800_dkae091-B7","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper#","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med"},{"key":"2024050202521434800_dkae091-B8","doi-asserted-by":"crossref","first-page":"e0096923","DOI":"10.1128\/aac.00969-23","article-title":"Could an optimized joint pharmacokinetic\/pharmacodynamic target attainment of continuous infusion ceftazidime-avibactam be a way to avoid the need for combo therapy in the targeted treatment of deep-seated DTR Gram-negative infections?","volume":"67","author":"Gatti","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2024050202521434800_dkae091-B9","doi-asserted-by":"crossref","first-page":"106765","DOI":"10.1016\/j.ijantimicag.2023.106765","article-title":"Pharmacokinetics\/pharmacodynamics of ceftobiprole in patients on extracorporeal membrane oxygenation","volume":"61","author":"Coppens","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"2024050202521434800_dkae091-B10","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.accpm.2019.02.015","article-title":"PHARMECMO: therapeutic drug monitoring and adequacy of current dosing regimens of antibiotics in patients on extracorporeal life support","volume":"38","author":"Bougl\u00e9","year":"2019","journal-title":"Anaesth Crit Care Pain Med"},{"key":"2024050202521434800_dkae091-B11","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/FTD.0000000000000369","article-title":"Ex vivo model to decipher the impact of extracorporeal membrane oxygenation on beta-lactam degradation kinetics","volume":"39","author":"Leven","year":"2017","journal-title":"Ther Drug Monit"},{"key":"2024050202521434800_dkae091-B12","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1164\/rccm.202210-2000ED","article-title":"Adequate antimicrobial dosing in critically ill patients receiving extracorporeal membrane oxygenation: where to go from here?","volume":"207","author":"Spriet","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2024050202521434800_dkae091-B13","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13613-023-01134-9","article-title":"Antibiotic stewardship in the ICU: time to shift into overdrive","volume":"13","author":"Mokrani","year":"2023","journal-title":"Ann Intensive Care"},{"key":"2024050202521434800_dkae091-B14","doi-asserted-by":"crossref","first-page":"154301","DOI":"10.1016\/j.jcrc.2023.154301","article-title":"A descriptive pharmacokinetic\/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam for treating DTR gram-negative infections in a case series of critically ill patients undergoing continuous veno-venous haemodiafiltration (CVVHDF)","volume":"76","author":"Gatti","year":"2023","journal-title":"J Crit Care"},{"key":"2024050202521434800_dkae091-B15","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1592\/phco.23.3.369.32100","article-title":"Retrospective review of neurotoxicity induced by cefepime and ceftazidime","volume":"23","author":"Chow","year":"2003","journal-title":"Pharmacotherapy"},{"key":"2024050202521434800_dkae091-B16","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jns.2019.01.018","article-title":"Serious central nervous system side effects of cephalosporins: a national analysis of serious reports registered in the French pharmacovigilance database","volume":"398","author":"Lacroix","year":"2019","journal-title":"J Neurol Sci"},{"key":"2024050202521434800_dkae091-B17","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.cmi.2020.11.031","article-title":"Ceftazidime\/avibactam neurotoxicity in an adult patient with normal renal function","volume":"27","author":"Pingue","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"2024050202521434800_dkae091-B18","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/jac\/dkad367","article-title":"Therapeutic drug monitoring of ceftazidime\/avibactam: why one leg is not enough to run","volume":"79","author":"Gatti","year":"2024","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/5\/1182\/57368320\/dkae091.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/5\/1182\/57368320\/dkae091.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T02:54:16Z","timestamp":1714618456000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/79\/5\/1182\/7636754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,28]]},"references-count":18,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,3,28]]},"published-print":{"date-parts":[[2024,5,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkae091","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5]]},"published":{"date-parts":[[2024,3,28]]}}}